![Valerie Salentey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Valerie Salentey is currently the Director of Regulatory Affairs & Quality Assurance at Sensorion SA since 2020.
Prior to this, she worked as the Head of Regulatory Affairs at Neovacs SA from 2018 to 2020, Head of Regulatory Affairs at PPD France SAS in 2018, and Head of Regulatory Affairs at Genethon from 2016 to 2018.
She also worked as the Head of Regulatory Affairs at Cytheris SA from 2008 to 2013.
Aktive Positionen von Valerie Salentey
Unternehmen | Position | Beginn |
---|---|---|
SENSORION | General Counsel | 01.04.2020 |
Ehemalige bekannte Positionen von Valerie Salentey
Unternehmen | Position | Ende |
---|---|---|
NEOVACS | General Counsel | 01.03.2020 |
PPD France SAS
![]() PPD France SAS Miscellaneous Commercial ServicesCommercial Services PPD France SAS provides technical analyzes,tests and inspection services. The company is headquartered in Ivry sur Seine, France. | General Counsel | 01.10.2018 |
Genethon
![]() Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | General Counsel | 01.01.2018 |
Cytheris SA
![]() Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | General Counsel | 01.08.2013 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
NEOVACS | Health Technology |
SENSORION | Health Technology |
Private Unternehmen | 3 |
---|---|
Genethon
![]() Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
Cytheris SA
![]() Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
PPD France SAS
![]() PPD France SAS Miscellaneous Commercial ServicesCommercial Services PPD France SAS provides technical analyzes,tests and inspection services. The company is headquartered in Ivry sur Seine, France. | Commercial Services |